medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2021, Number 4

<< Back Next >>

An Med Asoc Med Hosp ABC 2021; 66 (4)

Recurrence and clinical-pathologic characteristics in the risk groups stated by Oncotype Dx, original and TAILORx, in early stage breast cancer

Amador GG, Andrade MRA, Martínez HJF, Cwilich RG, Serrano OJA

Language: Spanish
References: 28
Page: 263-272
PDF size: 333.39 Kb.


ABSTRACT

Introduction: Oncotype Dx® predicts the risk of recurrence and supports the prescription of adjuvant chemotherapy in early breast cancer with hormone receptor positive, HER2 negative, and node negative or up to three positive. Objective: To determine the frequency of recurrence and the clinicopathological characteristics in the risk groups established by Oncotype Dx®, according to the traditional recurrence score and TAILORx. Material and methods: Women > 18 years of age with early breast cancer (stage I-IIB), Hormone receptor +/ HER2 neg, and negative or 1-3 positive nodes were included. Clinicopathological characteristics, recurrence, and recurrence-free survival were analyzed in the low, intermediate and high risk groups. Results: Original classification: low risk 72 cases (52.94%), intermediate risk 49 (36.03%) and high risk 15 (11.03%). TAILORx classification: 28 patients (20.59%), 86 (63.24%) and 22 (16.18%) had low risk, intermediate and high risk. Recurrence was observed in 13/88 cases (14.8%); the recurrence free survival was 91.3, 84.8 and 55.6% for the low, intermediate and high risk original groups and 100, 86.2 and 66.7% in those groups according to TAILORx's score. Conclusions: The TAILORx score is more accurate in distinguishing the group with a high risk of recurrence (16.8%), in early breast cancer, positive hormone receptors, negative HER2 requiring adjuvant chemotherapy, which is characterized by lower estrogen receptor expression and recurrence-free survival.


REFERENCES

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71 (3): 209-249. doi: 10.3322/caac.21660.

  2. American Cancer Society. Breast Cancer Facts & Figures 2019-2020. Atlanta: American Cancer Society, Inc, 2019. [Consulted 26 February 2021] Available in: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf

  3. Walks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019; 321 (3): 288-300.

  4. Kim EJ, Park HS, Kim JY, Kim SI, Cho YU, Park BW. Assessment of the Prognostic Staging System of American Joint Committee on Cancer 8th Edition for Breast Cancer: Comparisons with the Conventional Anatomic Staging System. J Breast Cancer. 2020; 23 (1): 59-68.

  5. Davies C, Godwin J, Gray R, Clarke M, Darby S, McGale P et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378: 771-784.

  6. Clarke M, Collins R, Davies C, Godwin J, Gran R, Peto R. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 351 (9114): 1451-1467.

  7. Peto R, Davies C, Godwin J, Gray R, Pan H C, Clarke M et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012; 379: 432-444.

  8. Sparano JA, Paik S. Development of the 21-Gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26 (5): 721-728.

  9. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004; 9 (6): 606-616.

  10. Rakha EA, Reis-Fihlo JS, Baehner F, Dabbs DJ, Decker T, Eusebi V et al. Breast Cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010; 12 (4): 207.

  11. Van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415: 530-36.

  12. Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016; 375 (8): 717-729.

  13. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vivkery T et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27: 1160-1167.

  14. Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013; 31: 2783-2790.

  15. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011; 17 (18): 6012-6020.

  16. Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018; 4 (4): 545-553.

  17. Sparano J, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 2008; 26: 721-728.

  18. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351: 2817-2826.

  19. Albain KS, Barlow WE, Shak S, Hortobagy GN, Livingston RB, Yeh IT et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010; 11 (1): 55-65.

  20. Sparano JA, Gray RJ, Makower DF, Protchard KI, Albain KS, Hayes DF et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018; 379 (2): 111-121.

  21. Gerson R, Alban LF, Villalobos A, Serrano JA. Características clinicopatológicas, pronóstico e influencia en el tratamiento adyuvante en los grupos de riesgo de recurrencia determinados por el perfil de expresión de 21 genes, Oncotype Dx, en cáncer de mama temprano. Gac Med Mex. 2012; 148 (2): 117-124.

  22. Bargallo JE, Lara F, Shaw-Dulin R, Pérez-Sánchez V, Villarreal-Garza C, Maldonado-Martínez H et al. A study of the impact of the 21-gene breast cancer assay on use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital. J Surg Oncol. 2015; 111: 203-207.

  23. Huang JL, Kizy S, Marmor S, Altman A, Blaes A, Beckwith H et al. Tumor grade and progesterone receptorstatus predict 21-gene recurrence scorein early stage invasive breast carcinoma. Breast Cancer Res Treat. 2018; 172 (3): 671-677.

  24. Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019; 380: 2395-2405.

  25. Zhang Y, Zhou Y, Mao F,Yao R, Sun Q. Ki67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast carcinoma recurrence risk: a consecutive cohort study. Cance Comm (Lond). 2020; 40 (4): 181-193.

  26. Henderson J, Adams P, Barber K. Factors determining anthracycline use in hormone receptor positive, early-stage breast cancer. Clin Breast Cancer. 2019; 19: e475-e480.

  27. Jasem J, Fisher C, Amini A, Shagisultanova E, Ravinotvich R, Borges V et al. The 21-gene recurrence score assay for node-positive, early-stage breast cancer and impact of RxPONDER trialon chemotherapy decision-making: have clinicians already decided? J Natl Compr Canc Netw. 2017; 15 (4): 494-503.

  28. Albain KS, Paik S, Van't Verr L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast. 2009; (Suppl 3): S141-S145.



EVIDENCE LEVEL

II




2020     |     www.medigraphic.com